Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). (Q40465372)
Jump to navigation
Jump to search
scientific article published on January 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). |
scientific article published on January 2005 |
Statements
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104) (English)
Carmen Scheibenbogen
Ulrich Keilholz
Anne Letsch
Alexander Schmittel
Anne Marie Asemissen
Kurt Gehlsen